Exam 2 drugs Flashcards
albuterol
SABA
asthma, COPD
levalbuterol
SABA
asthma, COPD
ipratropium
SAMA
asthma, COPD
prednisone, dexamethasone
systemic corticosteroids
asthma, COPD
budesonide
ICS
asthma, COPD
fluticasone
ICS
asthma, COPD
ciclesonide
new ICS
asthma
salmeterol
LABA
asthma, COPD
formoterol
LABA
asthma, COPD
tiotropium
LAMA
asthma, COPD
cromolyn
cromoglycates - alter function of chloride channels – inhibit cellular activation
asthma
theophylline
methylxanthines - inhibits PDE = bronchodilator
asthma
zileuton
leukotriene modifier- 5- lipoxygenase inhibitor
asthma (not used)
zafirleukast
leukotriene modifier - cysteinyl leukotriene-receptor antagonist
asthma (not used)
Montelukast
leukotriene modifier - cysteinyl leukotriene-receptor antagonist
asthma (+allergic rhinitis)
umeclidinium
LAMA
COPD
aclidinium
LAMA
COPD
revefenacin
LAMA
COPD
glycopyrrolate
LAMA
COPD
oldaterol
LABA
COPD
arfomoterol
LABA
COPD
Roflumilast
inhibits PDE4 = decreases inflammation
severe COPD with bronchitis & AE-COPD
DM
cough
benzonatate
polyglycol derivative
cough
guaifenesin
expectorant for cough
antihistamines
antimuscarinic effects for cough
decongestants
decrease PND for cough
bupropion
smoking cessation, MDD, seasonal affective disorder
*dont give with anxiety! or seizure hx
calcium
osteoporosis (1000-1200)
HRT
estrogen +/- progestin
not 1st line for osteoporosis - now causes VTE, CA, CVA
tamoxifen
SERM - selective estrogen receptor modulator
osteoporosis
raloxifene
SERM - selective estrogen receptor modulator
osteoporosis
denosumab
anti-rank ligand - prevents preosteoclasts–>osteoclasts
osteoporosis, mets from solid tumors
alendronate
bisphos - incorporates into bone, gets released by osteoclasts = osteoclast apoptosis
osteoporosis
risendronate
bisphos - incorporates into bone, gets released by osteoclasts = osteoclast apoptosis
osteoporosis
zoledronic acid
bisphos - incorporates into bone, gets released by osteoclasts = osteoclast apoptosis
osteoporosis
teriparatide
PTH/PTHrP analog - increases osteoblasts, increase Ca2+ in GI tract and kidney
osteoporosis with high risk of fracture
aboloparatide
PTH/PTHrP analog - increases osteoblasts, increase Ca2+ in GI tract and kidney
osteoporosis with high risk of fracture
romosumab
sclerostin inhibitor - stimulates osteoblasts
osteoporosis
levothyroxine
T4–>T3
hypothyroidism
liothyronine
T3
hypothyroidism
liotrix
T3 & T4
hypothyroidism
PTU
thionamide - blocks conversion in thyroid and liver
hyperthyroidism in 1st trimester pregnancy, thyroiditis (thyroid storm)
methimazole
thionamide - blocks conversion just in thyroid
hyperthyroidism
RAI
sodium iodine I-131 - inflammation = destroys thyroid
hyperthyroidism
steroid for hyperthyroidism sxs
dexamethasone
metformin
biguanides- decreases hepatic glucose production, increases GLP1
pre-DM, DM, PCOS
glyburide
sulfonyurea- binds ATP K+ channel = increased insulin secretion
DM (not used)
glimepiride
sulfonyurea - binds ATP K+ channel = increased insulin secretion
DM (not used in elderly)
glipizide
sulfonyurea OF CHOICE - binds ATP K+ channel = increased insulin secretion
DM
nateglinide
meglitinides - binds ATP K+ channel = increased insulin secretion
DM
repaglinide
meglitinides - binds ATP K+ channel = increased insulin secretion
DM
pioglitazone
TZD - ppar-y agonist
DM (favorable lipid effects)
rosiglitazone
TZD - ppar-y with ppar-a activity
DM
acarbose
alpha-glucosidase inhibitor - decreases glucose absorption at SI brush border
DM
miglitol
alpha-glucosidase inhibitor - decreases glucose absorption at SI brush border
DM
liraglutide
GLP-1 agonists - stimulates insulin, inhibits glucagon secretion, hepatic glucose production, gastric emptying, appetite
DM, *weight loss
semaglutide
GLP-1 agonists - stimulates insulin, inhibits glucagon secretion, hepatic glucose production, gastric emptying, appetite
DM - *most potent A1C lowering
exenatide
GLP-1 agonists - stimulates insulin, inhibits glucagon secretion, hepatic glucose production, gastric emptying, appetite
DM
lixisenatide
GLP-1 agonists - stimulates insulin, inhibits glucagon secretion, hepatic glucose production, gastric emptying, appetite
DM
dulaglutide
GLP-1 agonists - stimulates insulin, inhibits glucagon secretion, hepatic glucose production, gastric emptying, appetite
DM
sitagliptin
DPP-4 inhibitor - prolong active incretin levels
DM
saxagliptin
DPP-4 inhibitor - prolong active incretin levels
DM
linagliptin
DPP-4 inhibitor - prolong active incretin levels
DM
alogliptin
DPP-4 inhibitor - prolong active incretin levels
DM
canagliflozin
SGLT-2 inhibitor - decreases glucose and Na reabsorption, increase urinary glucose/Na excretion
DM
empagliflozin
SGLT-2 inhibitor - decreases glucose and Na reabsorption, increase urinary glucose/Na excretion
DM *agent of choice!!
ertugliflozin
SGLT-2 inhibitor - decreases glucose and Na reabsorption, increase urinary glucose/Na excretion
DM
dapagliflozin
SGLT-2 inhibitor - decreases glucose and Na reabsorption, increase urinary glucose/Na excretion
DM